Shenzhen New Industries Biomedical (300832) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.069x

Based on the latest financial reports, Shenzhen New Industries Biomedical (300832) has a cash flow conversion efficiency ratio of 0.069x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥606.21 Million ≈ $88.71 Million USD) by net assets (CN¥8.74 Billion ≈ $1.28 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Shenzhen New Industries Biomedical - Cash Flow Conversion Efficiency Trend (2012–2024)

This chart illustrates how Shenzhen New Industries Biomedical's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 300832 total liabilities for a breakdown of total debt and financial obligations.

Shenzhen New Industries Biomedical Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Shenzhen New Industries Biomedical ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
PTT Global Chemical Public Company Limited
BK:PTTGC
-0.057x
Olympic Circuit Technology Co Ltd
SHG:603920
0.048x
Reinet Investments SCA
JSE:RNI
0.000x
Gerdau S.A
MX:GGBN
0.053x
Compagnie de l'Odet
PA:ODET
-0.027x
Porsche Automobil Holding SE
XETRA:PAH3
-0.006x
Jiangsu Lettall Electronic Co Ltd
SHG:603629
0.067x
TKMS AG & Co KGaA
XETRA:TKMS
N/A

Annual Cash Flow Conversion Efficiency for Shenzhen New Industries Biomedical (2012–2024)

The table below shows the annual cash flow conversion efficiency of Shenzhen New Industries Biomedical from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see 300832 market cap overview.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 CN¥8.58 Billion
≈ $1.26 Billion
CN¥1.36 Billion
≈ $198.49 Million
0.158x -15.87%
2023-12-31 CN¥7.54 Billion
≈ $1.10 Billion
CN¥1.42 Billion
≈ $207.54 Million
0.188x +25.01%
2022-12-31 CN¥6.40 Billion
≈ $936.45 Million
CN¥962.39 Million
≈ $140.83 Million
0.150x +9.15%
2021-12-31 CN¥5.61 Billion
≈ $821.21 Million
CN¥773.22 Million
≈ $113.15 Million
0.138x -32.23%
2020-12-31 CN¥4.80 Billion
≈ $703.01 Million
CN¥976.65 Million
≈ $142.92 Million
0.203x -23.28%
2019-12-31 CN¥3.14 Billion
≈ $459.30 Million
CN¥831.73 Million
≈ $121.71 Million
0.265x -10.68%
2018-12-31 CN¥2.37 Billion
≈ $346.26 Million
CN¥701.97 Million
≈ $102.72 Million
0.297x +0.19%
2017-12-31 CN¥1.77 Billion
≈ $259.33 Million
CN¥524.73 Million
≈ $76.78 Million
0.296x -13.68%
2016-12-31 CN¥1.42 Billion
≈ $207.68 Million
CN¥486.81 Million
≈ $71.24 Million
0.343x +14.71%
2015-12-31 CN¥1.02 Billion
≈ $149.72 Million
CN¥305.93 Million
≈ $44.77 Million
0.299x -27.98%
2014-12-31 CN¥610.52 Million
≈ $89.34 Million
CN¥253.47 Million
≈ $37.09 Million
0.415x +13.70%
2013-12-31 CN¥378.84 Million
≈ $55.44 Million
CN¥138.33 Million
≈ $20.24 Million
0.365x +62.39%
2012-12-31 CN¥248.18 Million
≈ $36.32 Million
CN¥55.80 Million
≈ $8.17 Million
0.225x --

About Shenzhen New Industries Biomedical

SHE:300832 China Medical Devices
Market Cap
$5.55 Billion
CN¥37.91 Billion CNY
Market Cap Rank
#3347 Global
#502 in China
Share Price
CN¥48.25
Change (1 day)
-0.29%
52-Week Range
CN¥44.82 - CN¥70.18
All Time High
CN¥98.01
About

Shenzhen New Industries Biomedical Engineering Co., Ltd., engages in the research, development, production, and sale of clinical laboratory instruments and in vitro diagnostic reagents to hospitals in China and internationally. It offers immunoassay machine, biochemistry/electrolyte, integrated system, lab automation, molecular diagnostics, hemolumi and rapid test solutions. The company was found… Read more